TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$200 Million

Amyris, Inc.


Placement Agent, June 2020

Amyris, Inc.

Amyris is a leading synthetic biology Company focused on manufacturing sustainable ingredients and products across various end-markets, including personal care, beauty and wellness, and healthcare. The current tech platform has been in active use since 2007, with integration into the Company’s current infrastructure completed in 2011. The Company’s proven technology platform engineers microbes, such as yeast, and utilizes them as catalysts to metabolize plant-sourced sugars into high-value molecules. The platform has unique application in the industrial fermentation process (i.e., replacing existing complex and expensive manufacturing processes). This has enabled Amyris to produce at-scale, at substantially lower prices than current providers, in a sustainable and disruptive fashion. Key additional tech platform attributes include proprietary tools for computational assessment, strain construction, screening / analytics and advanced automation / data integration. Over time, Amyris has dramatically scaled the efficiency of its core tech platform, reducing time-to-market for novel molecules in development to less than ~1 year (from ~7 years, historically) yielding 15+ commercial products sold to >3,000 brands globally. Leveraging its core synthetic biology platform technology, Amyris engineers and manufactures a variety of sustainable ingredients (e.g., farnesene, patchouli, squalane) for world-leading brands and retailers including Sephora, L’Oreal, Estee Lauder, Walmart and Target. The Company also has several clean, sustainable consumer health & beauty product brands developed in-house and marketed direct-to-consumer, including Biossance (skin care), Pipette (baby products) and Purecane (natural sweetener).